“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...

Imfinzi plus FLOT chemotherapy significantly improves overall survival in resectable G/GEJ adenocarcinoma compared to placebo ...

Malik, 57, is accused of establishing the 'cash cow' firm alongside a pharmacist, a registered scientist and his own former ...

Daiichi Sankyo Company, Limited ( OTCPK:DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions October 21, 2025 8:00 AM EDT ...

Influenza vaccination provided moderate protection against infection among UK health care workers during the 2023 to 2024 season.

The Nifty 50 index is expected to face resistance at the 25,900–26,000 zone on the Muhurat Trading day, while support is ...

Thousands of Slovaks lined up to be tested for the coronavirus in the country's worst-affected areas on Friday, taking part in a pilot programme that will eventually go nationwide.

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...